news-details
Health,Watchlist,healthcare stocks

4 HealthTech Stocks Trending Now NTLA, SKIN, EW, ALC stock

Powered by healthtechmovers.com

According to healthtechmovers.com, there are a few trending healthtech stocks that have recently received buy ratings and showing positive investor sentiment, as well as news headlines. With that said, the editors over at healthtechmovers.com, are adding the stocks below to their healthtech stock watchlist.  That staff here at marketmoversinsider.com, will continue to monitor these healthtech companies to see if the momentum continues. MarketMoversInsider.com is also looking into these tickers BMRN, PEPG, BLCO, COO, SAGE..

Intellia Therapeutics, NTLA
Recent NTLA Stock Price: $62.53
Summary:
Intellia Therapeutics is a leading clinical-stage genome editing company focused on developing CRISPR/Cas9-based therapeutics. The company is pursuing two primary approaches to fully realize the transformative potential of CRISPR/Cas9 in vivo programs that use intravenously administered CRISPR as the therapy and ex vivo programs that use CRISPR to create the therapy by using engineered human cells.'

David Lebovitz analyst at Citigroup reiterates coverage on Intellia Therapeutics (NTLA) stock in the energy sector with a Sell rating and has set NTLA's stock price target at $ 50.

TipRanks.com reports that Intellia Therapeutics currently has 15 analysts offering 12-month price targets on NTLA and the consensus is a Moderate Buy rating with an average stock price target of $110.46.  The most recent NTLA stock price we have is $62.53 and we are not making any NTLA forecasts at this time.

In addition, TradingView issued a n/a rating for NTLA over the next month, Barchart.com has a hold rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on NTLA. marketmoversinsider.com is not recommending this stock, we are just providing you with compiled information.

For the complete breakdown on NTLA, please click here >>

Beauty Health, SKIN
Recent SKIN Stock Price: $11.8
Summary:
The Beauty Health Company is a beauty health company. Its flagship brand HydraFacial is a non-invasive and approachable beauty health platform and ecosystem with a powerful community of estheticians, consumers and partners, bridging medical and consumer retail to democratize and personalize skin care solutions for the masses. The Beauty Health Company, formerly known as Vesper Healthcare Acquisition Corp., is based in CHICAGO, Utah.

Oliver Chen analyst at Cowen & Co. reiterates coverage on Beauty Health (SKIN) stock in the energy sector with a Buy rating and has set SKIN's stock price target at $ 20.

TipRanks.com reports that Beauty Health currently has 8 analysts offering 12-month price targets on SKIN and the consensus is a Strong Buy rating with an average stock price target of $22.63.  The most recent SKIN stock price we have is $11.8 and we are not making any SKIN forecasts at this time.

In addition, TradingView issued a n/a rating for SKIN over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on SKIN. marketmoversinsider.com is not recommending this stock, we are just providing you with compiled information.

For the complete breakdown on SKIN, please click here >>

Edwards Lifesciences, EW
Recent EW Stock Price: $87.19
Summary:
Edwards Lifesciences Corporation deals in products and technologies aimed at treating advanced cardiovascular diseases, especially structural heart disease in critically ill patients. The company is the world's leading manufacturer of tissue heart valves and repair products used to replace or repair a patient's diseased or defective heart valve. Edwards is also a leading player in hemodynamic monitoring systems used to measure a patient's cardiovascular function in the hospital setting. The company's products and technologies are categorized into four main areas: Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), Surgical Structural Heart, and Critical Care.

Suraj Kalia analyst at Oppenheimer reiterates coverage on Edwards Lifesciences (EW) stock in the energy sector with a Buy rating and has set EW's stock price target at $ 128.

TipRanks.com reports that Edwards Lifesciences currently has 16 analysts offering 12-month price targets on EW and the consensus is a Strong Buy rating with an average stock price target of $116.13.  The most recent EW stock price we have is $87.19 and we are not making any EW forecasts at this time.

In addition, TradingView issued a n/a rating for EW over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on EW. marketmoversinsider.com is not recommending this stock, we are just providing you with compiled information.

For the complete breakdown on EW, please click here >>

Alcon, ALC
Recent ALC Stock Price: $65.23
Summary:
Alcon Inc. researches, develops, manufactures, distributes, and sells a full suite of eye care products. Alcon operates within two segments, Surgical and Vision Care. The Surgical segment is focused on ophthalmic products for cataract surgery, vitreoretinal surgery, refractive laser surgery and glaucoma surgery, and includes implantables, consumables, and surgical equipment required for these procedures. The Vision Care segment comprises daily disposable, reusable and color-enhancing contact lenses, and a comprehensive portfolio of ocular health products, including products for dry eye, contact lens care, and ocular allergies, as well as ocular vitamins and redness relievers.

Ryan Zimmerman analyst at BTIG reiterates coverage on Alcon (ALC) stock in the energy sector with a Buy rating and has set ALC's stock price target at $ 80.

TipRanks.com reports that Alcon currently has 12 analysts offering 12-month price targets on ALC and the consensus is a Moderate Buy rating with an average stock price target of $79.71.  The most recent ALC stock price we have is $65.23 and we are not making any ALC forecasts at this time.

In addition, TradingView issued a n/a rating for ALC over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on ALC. marketmoversinsider.com is not recommending this stock, we are just providing you with compiled information.

For the complete breakdown on ALC, please click here >>



The editors at marketmoversinsider.com use a variety of research tools to generate our watchlists and research reports.  One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals.  TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star RankingTM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>

MarketMoversInsider.com is for serious traders.

Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.    
==============================================================================